A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Cediranib; Sunitinib
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 22 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2016.
- 22 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016.